Directors Brett Gardiner and Rachel Howard attended the World Pharma Pricing and Market Access Congress in Amsterdam in March.
This two-day event was attended by over 600 delegates, including a number of payers from Europe, the US and Latin America, plus representatives from the industry and other market access organizations. In the morning plenary sessions, we heard a range of perspectives on value, demonstrating that “value is in the eye of the beholder”. A major focus was the new challenges facing Health Technology Assessment (HTA) organizations in view of the expanding pipeline of Advanced Therapy Medicinal Products (ATMPs) such as cell and gene therapy. There was much discussion about how these products, with their high upfront costs and inherent limitations will necessitate the creation of a new access model. To allow negotiations to move forward and ensure more timely access to patients, we need to look at using innovative payment models such as outcomes-based contracting and find ways of addressing uncertainty.
Find out more about their time at the event.
Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom